Last reviewed · How we verify
Ramucirumab DP (IMC-1121B)
Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.
Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis. Used for Non-small cell lung cancer, gastric cancer, and other solid tumors.
At a glance
| Generic name | Ramucirumab DP (IMC-1121B) |
|---|---|
| Also known as | IMC-1121B, LY3009806 |
| Sponsor | Eli Lilly and Company |
| Drug class | VEGF inhibitor |
| Target | VEGFR2 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to VEGFR2, Ramucirumab DP prevents the activation of downstream signaling pathways that promote angiogenesis, thereby inhibiting tumor growth and metastasis. This mechanism of action is particularly relevant in the treatment of various cancers.
Approved indications
- Non-small cell lung cancer, gastric cancer, and other solid tumors
Common side effects
- Hypertension
- Fatigue
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) (PHASE2, PHASE3)
- Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (PHASE2, PHASE3)
- Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) (PHASE2)
- A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma (PHASE3)
- Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma (PHASE2)
- Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients (PHASE2)
- A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramucirumab DP (IMC-1121B) CI brief — competitive landscape report
- Ramucirumab DP (IMC-1121B) updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI